GOLDEN, Colo. — November 17, 2020 — PharmaJet
®, the maker of innovative, needle-free injection technology, today announced that its Tropis
® Needle-free Injection System will be used by Diomics, a San Diego-based biotech company, to deliver a biopolymer to detect the formation of an immune response to a SARS-CoV-2 protein. The company was awarded over $2 million by the Department of Defense to accelerate testing of its Diocheck
™ system and is expected to begin human clinical trials in December 2020.
